Biofrontera Inc. SEC filings BFRI
Biofrontera Inc. has 365 filings in SEC EDGAR's recent list, going back to May 7, 2021. Its latest annual report, Form 10-K, was filed on Mar 19, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 14, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 30, 2026 | Apr 30, 2026 |
| DEF 14A | Proxy statement | Aug 5, 2025 | Aug 5, 2025 |
| PRE 14A | Preliminary proxy statement | Jul 25, 2025 | Jul 25, 2025 |
| DEF 14A | Proxy statement | Apr 30, 2025 | Apr 30, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2025 | Apr 18, 2025 |
| DEF 14A | Proxy statement | Apr 17, 2024 | Apr 17, 2024 |
| DEF 14A | Proxy statement | Mar 21, 2024 | Mar 20, 2024 |
| PRE 14A | Preliminary proxy statement | Mar 8, 2024 | Mar 8, 2024 |
| DEF 14A | Proxy statement | Nov 17, 2023 | Nov 17, 2023 |
| DEF 14A | Proxy statement | Apr 21, 2023 | Apr 21, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 11, 2023 | Apr 11, 2023 |
| DEFA14A | Additional proxy material | Dec 8, 2022 | — |
| DEFA14A | Additional proxy material | Nov 29, 2022 | — |
| DEFA14A | Additional proxy material | Nov 21, 2022 | — |
| DEF 14A | Proxy statement | Nov 8, 2022 | Nov 8, 2022 |
Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BFRI (Nasdaq), BFRIW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Woburn, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1858685
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.